Worldwide Sepsis Industry to 2030 – Players Include Baxter Healthcare, Enlivex Therapeutics and Ono Pharmaceutical Among Others – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Sepsis – Market Insight, Epidemiology and Market Forecast – 2030” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report delivers an in-depth understanding of the Sepsis, historical and forecasted epidemiology as well as the Sepsis market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The Sepsis market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Sepsis market size from 2018 to 2030. The Report also covers current Sepsis treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Key Findings

• In 2020, the total estimated Incident Cases of Sepsis were 3,400,940 cases in the 7MM, which is expected to increase in the forecast period (2021-2030).
• US is the major contributor (55.01%, in 2020) to the incident population of Sepsis in the 7MM, with 1,870,897 cases.
• Out of EU5 countries, Germany had the highest incident cases in 2020 followed by the UK and Spain. France accounted for the least number of cases in 2020.

The United States Market Outlook

This section provides the total Sepsis market size and; market size by therapies in the United States.

EU-5 Market Outlook

The total Sepsis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total Sepsis market size and market size by therapies in Japan are provided.

Scope of the Report

• The report covers the descriptive overview of Sepsis, explaining its causes, symptoms, pathophysiology, genetic basis, and currently available therapies.
• Comprehensive insight has been provided into the Sepsis epidemiology and treatment.
• Additionally, an all-inclusive account of both the current and emerging therapies for Sepsis is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of the Sepsis market; historical and forecasted is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Sepsis market.

Report Highlights

• The robust pipeline with novel MOA and oral ROA, increasing incidence, effectiveness of drugs as both mono and combination therapy will positively drive the Sepsis market.
• The companies and academics are working to assess challenges and seek opportunities that could influence Sepsis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Major players are involved in developing therapies for Sepsis. The launch of emerging therapies will significantly impact the Sepsis market.
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Companies Mentioned

• ABIONYX Pharma
• Adrenomed
• AM-Pharma
• Asahi Kasei Pharma Corp.
• Baxter Healthcare Corporation
• BioMarck Pharmaceuticals
• Enlivex Therapeutics
• Inotrem
• La Jolla Pharmaceuticals
• Ono Pharmaceutical
• Par Pharmaceutical
• Revimmune
• Shionogi
• Vivacelle Bio

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/8957tl

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900